Eli Lilly’s Omvoh Yields 92.4% Remission at 3-Year VIVID-2 Extension
Eli Lilly’s Phase 3 VIVID-2 open-label extension of Omvoh in Crohn’s showed 92.4% clinical and 91.2% corticosteroid-free remission at 152 weeks with minimal hospitalizations or surgeries. VIVID-1 and LUCENT-3 data show Omvoh as the first IL-23p19 inhibitor with efficacy beyond 4 years in ulcerative colitis and 3 years in Crohn’s.
1. Study Design and Patient Outcomes
The VIVID-2 open-label extension enrolled patients with moderate-to-severe Crohn’s disease who had previously responded to Omvoh (mirikizumab-mrkz). After three years of continuous treatment, 92.4% of participants maintained clinical remission and 91.2% achieved corticosteroid-free remission, with very few requiring hospitalization or surgery.
2. Comparative Efficacy Across Trials
Data from the preceding VIVID-1 trial in Crohn’s and LUCENT-3 in ulcerative colitis reinforce Omvoh’s durable performance, marking it as the first IL-23p19 inhibitor to sustain remission for at least four years in ulcerative colitis and three years in Crohn’s disease while minimizing invasive interventions.
3. Commercial Outlook and Next Steps
With robust long-term efficacy, Eli Lilly plans to advance Omvoh toward regulatory submission in both indications. Management highlights that sustained control of inflammation could alter disease progression and position Omvoh as a market leader in IL-23p19 therapeutics.